New Leadership at Evoke Pharma with Ben Smeal Joining the Board
Evoke Pharma, Inc. (NASDAQ: EVOK), a prominent specialty pharmaceutical firm, has added Ben Smeal to its Board of Directors. This strategic appointment comes as a response to an obligation related to recent financing efforts by Nantahala Capital Management.
The Journey and Experience of Ben Smeal
With an impressive background in corporate governance and investment management, Mr. Smeal brings a wealth of experience. Prior to his focus on private investment, he contributed his expertise at Willett Advisors, which is associated with Michael R. Bloomberg, and Kenmare Management, a well-respected hedge fund. These roles have equipped him with an understanding of strategic business development and equity investments.
Marketing Expertise and Diverse Background
Additionally, Mr. Smeal's tenure as Marketing Director at Overstock.com allowed him to develop significant skills in traditional and digital marketing. This experience enhances his capability to foster growth and encourage innovative strategies within Evoke Pharma.
CEO Matt D'Onofrio's Statement
“We are thrilled to welcome Ben to our board,” shared Matt D'Onofrio, CEO. His deep knowledge in public equities and corporate leadership promises to drive forward the mission of making GIMOTI more accessible to patients in need.
Ben Smeal's Enthusiastic Response
In his own words, Ben expressed excitement about joining Evoke’s Board of Directors: “I am honored to join Evoke’s Board of Directors. The company’s unwavering dedication to improving patient outcomes in such an underserved area of medicine resonates deeply with me, and I look forward to working with the team to drive future success.”
About Evoke Pharma, Inc.
Evoke Pharma focuses on developing innovative medicines aimed at treating gastrointestinal (GI) disorders. Their flagship product, GIMOTI, is a nasal spray formulation designed to relieve symptoms of diabetic gastroparesis, a condition impacting many adults globally.
The Impact of Diabetic Gastroparesis
This condition poses significant challenges as it delays gastric emptying, leading to severe gastrointestinal symptoms and complicating the absorption of oral medications. Before GIMOTI's FDA approval, metoclopramide was only available in oral and injectable forms, making GIMOTI the sole drug currently approved to treat gastroparesis in the United States.
Accessing More Information
For further details about Evoke and their innovative products, visit their website at www.EvokePharma.com.
Frequently Asked Questions
1. What is Evoke Pharma's primary focus?
Evoke Pharma specializes in developing treatments for gastrointestinal disorders, particularly diabetic gastroparesis.
2. Who is Ben Smeal?
Ben Smeal is the newly appointed member of Evoke Pharma's Board of Directors, bringing extensive investment management and marketing experience.
3. What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide approved for the treatment of diabetic gastroparesis symptoms.
4. Why is the appointment of Ben Smeal significant?
His experience in corporate governance and marketing is expected to enhance Evoke Pharma's strategic direction and growth.
5. How can I learn more about Evoke Pharma?
For in-depth information about their products and updates, you can visit www.EvokePharma.com.
